New Zealand's BLIS Technologies rises; co gets Australia nod for active drug ingredient
29/03/2019 24:26
** Healthcare product maker BLIS Technologies Ltd BLT.NZ
rises as much as 5.9 pct to NZ$0.018, their highest since March
19
** Co says Australian Therapeutic Goods Administration,
approves BLIS M18, a probiotic strain Streptococcus salivarius
as an active ingredient for listed complementary medicines
urn:newsml:reuters.com:*:nNZWbwBc92
** Stock posts biggest intraday pct gain since March 6
** Stock down 5.6 pct this year as of last close
((aditya.srivastsav.thomsonreuters.com@reuters.net))
Recent news on BLIS Technologies
See all newsBrief: Blis Technologies Says Strong 1Q27 Supports Growth Outlook
New Zealand's BLIS Technologies Q1 revenue rises on ingredient sales growth
Brief: BLIS Technologies Posts Q1 EBITDA Of NZD 1.1 million
New Zealand's BLIS Technologies advances on upbeat annual results
Brief: BLIS Technologies Says Co Suffered Minimal Economic Loss From Uncertainty Surrounding Middle East